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Abstract
Background: Placental ischemia and hypertension, characteristic features of preeclampsia, are associated with
impaired cerebral blood flow (CBF) autoregulation and cerebral edema. However, the factors that contribute to
these cerebral abnormalities are not clear. Several lines of evidence suggest that angiotensin II can impact
cerebrovascular function; however, the role of the renin angiotensin system in cerebrovascular function during
placental ischemia has not been examined. We tested whether the angiotensin type 1 (AT1) receptor contributes to
impaired CBF autoregulation in pregnant rats with placental ischemia caused by surgically reducing uterine
perfusion pressure.
Methods: Placental ischemic or sham operated rats were treated with vehicle or losartan from gestational day (GD)
14 to 19 in the drinking water. On GD 19, we assessed CBF autoregulation in anesthetized rats using laser Doppler
flowmetry.
Results: Placental ischemic rats had impaired CBF autoregulation that was attenuated by treatment with losartan.
In addition, we examined whether an agonistic autoantibody to the AT1 receptor (AT1-AA), reported to be present
in preeclamptic women, contributes to impaired CBF autoregulation. Purified rat AT1-AA or vehicle was infused into
pregnant rats from GD 12 to 19 via mini-osmotic pumps after which CBF autoregulation was assessed. AT1-AA
infusion impaired CBF autoregulation but did not affect brain water content.
Conclusions: These results suggest that the impaired CBF autoregulation associated with placental ischemia is due,
at least in part, to activation of the AT1 receptor and that the RAS may interact with other placental factors to
promote cerebrovascular changes common to preeclampsia.
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Background
Preeclampsia is a complex syndrome of pregnancy that can
negatively impact multiple organ systems and promote
poor maternal and fetal outcomes. The brain is among the
organs impacted during preeclamptic pregnancies. Pre-
eclampsia increases the risk for maternal encephalopathies,
seizure, edema, and stroke both in the peripartum period
and even years into the postpartum period (reviewed in
[1]). Indeed, 40% of maternal deaths that result from pre-
eclampsia are related to cerebrovascular complications [2].
While the underlying mechanisms responsible for the in-
creased cerebrovascular risk during preeclampsia remain
incompletely understood, there is evidence both in patients
and in experimental animal models of preeclampsia sug-
gesting that impaired autoregulation of cerebral blood flow
(CBF) may be a factor [3–5]. However, the mechanisms re-
sponsible for the impaired autoregulation of CBF during
preeclampsia have yet to be elucidated.
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One potential system that may be involved is the
renin-angiotensin system (RAS). During normal preg-
nancies, the RAS is activated and plays a prominent role
in the expansion of the extracellular fluid volume that
accompanies normal pregnancy [6]. Blood pressure is
typically unchanged or lower under these circumstances
because of a reduced sensitivity to angiotensin II (AngII)
that occurs during pregnancy [7]. However, in pre-
eclamptic pregnancies, AngII sensitivity is increased and
may be an important factor associated with the patho-
physiology [8].
Evidence suggests that AngII causes cerebrovascular
dysfunction that is attenuated by blockade of the angio-
tensin type 1 (AT1) receptor [9, 10]. In addition, AngII
has been reported to directly alter CBF autoregulation in
a sex specific manner. For example, relative to males,
the ability of AngII to impair cerebral vascular responses
to the whisker barrel reflex are blunted in females, and
this protection results in part from the presence of es-
trogens [11]. While there is evidence that AT1 receptor
activation leads to cerebrovascular dysfunction, the con-
tribution of angiotensin receptors to impaired CBF auto-
regulation during pregnancy and preeclampsia remains
unclear.
In the present study, we utilized an established experi-
mental model of placental ischemia that mimics several
characteristics of human preeclampsia to examine the
role of AT1 receptors in CBF autoregulation. We previ-
ously reported that reducing uterine perfusion in the
pregnant rat causes placental ischemia and leads to a
marked impairment of CBF autoregulation [5]. In order
to examine the role of AT1 receptors, we first utilized
pharmacological blockade with losartan in placental is-
chemic rats. Next, we infused an agonistic AT1 receptor
autoantibody (AT1-AA) into pregnant rats that is re-
portedly increased in preeclamptic women [12] and en-
hances AT1 receptor sensitivity [13]. The results of the
present study suggest that the AT1 receptor partially
contributes to impaired CBF autoregulation in placental
ischemic rats.
Methods
Animals
Time-pregnant CD rats (a sub-strain of Sprague Dawley
rats) were obtained from Charles River Laboratories and
maintained in the Laboratory Animal Facilities at the
University of Mississippi Medical Center and maintained
in controlled temperature, humidity, and 12 h light/dark
conditions. Rats had continuous access to food and
water and were housed in pairs until day of surgery, after
which, rats were singly housed. All animal protocols
were approved by the Institutional Animal Care and Use
Committee (IACUC) at UMMC before the experiments
were conducted.
Placental ischemia induction and losartan treatment
On gestational day (GD) 14, rats were weighed and
weight-matched to sham or RUPP groups. Under isoflur-
ane anesthesia, silver clips were surgically placed on the
abdominal aorta, below the kidneys, and on both
branches of the uterine arteries before the first pup. This
procedure leads to reduction in utero-placental perfu-
sion pressure (RUPP) and placental ischemia. Rats in the
sham group were subjected to similar surgical interven-
tions with abdominal incision and exteriorization of
pups without clip placement. Carprofen (5 mg/kg) was
administered as a pre- and post- surgical analgesic.
Losartan (American Health Packaging, Columbus, OH)
was administered via drinking water to pregnant rats
from GD 14. Water intake was recorded daily from GD
14 to 19. Based on water intake, the rats in the sham
group received 16.1 ± 0.9 mg/kg/day while rats in the
RUPP group received 17.5 ± 1.3 mg/kg/day losartan (p =
0.50).
Mean arterial pressure and other characteristics
On GD 18, a catheter was surgically implanted in the left
carotid artery under isoflurane anesthesia. Blood pres-
sure was measured in conscious rats in restrainer cages
the morning of GD 19 via a carotid catheter connected
to a pressure gauge and PowerLab setup (ADInstru-
ments) as previously described [5]. Data were recorded
in real-time following a 30min acclimation period using
LabChart software. Mean arterial pressure was recorded
over a 30 min period. At the conclusion of the study, rats
were anesthetized with isoflurane, and an abdominal in-
cision was made in order to exteriorize the utero-
placental unit. The number of live and resorbed pups
was counted. Rats with no surviving pups (100% resorp-
tions) were not considered as pregnant and were ex-
cluded from analysis (n = 12 in RUPP, n = 4 in
RUPP+losartan).
Cerebral blood flow autoregulation
On GD 19, a separate group of rats were anesthetized
using ketamine (30 mg/kg, i.m.) and inactin (50 mg/kg,
i.p.). Once an anesthetic plane was achieved, rats were
instrumented with femoral vein catheters (for infusion of
saline and/or phenylephrine), a carotid catheter (for con-
tinuous recording of blood pressure), and tracheal tub-
ing (PE-240, for ventilation and monitoring of exhaled
carbon dioxide). Cranial windows were created by thin-
ning the skull until the brain surface vessels were visible,
without puncturing the underlying dura. A 4mm × 4
mm closed cranial window was created over the parietal
cortex, and probe holders were affixed to the skull. The
probes were in the region of the middle cerebral artery.
Respiration rate was set based on the body mass of the
rat according to manufacturer’s directions and was
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modified to maintain CO2 levels within physiological
range (PhysioSuite with MouseVent, Kent Scientific).
End-tidal CO2 has been shown to be a good indica-
tor of arterial pCO2 [14]. Phenylephrine (50 μg/mL
in saline) was infused via femoral vein catheter to
induce graded increases in blood pressure. Baseline
regional CBF was measured, and mean arterial pres-
sure (MAP) was then elevated in steps of 20 mmHg
up to 190 mmHg by graded intravenous infusion of
phenylephrine (0.5–5 μg/min). CBF was monitored
and recorded at each level of MAP using laser Dop-
pler flowmetry (Perimed). We previously published
using this method [5]. Autoregulatory index was cal-
culated as a ratio of the change in CBF and the
change in MAP. An autoregulatory index of 1 repre-
sents complete loss of autoregulation while 0 repre-
sents perfect autoregulation.
AT1-AA infusion
Mini-osmotic pumps (Alzet, model 2001), containing ei-
ther an agonistic autoantibody to the AngII type 1 re-
ceptor (AT1-AA) or vehicle (saline), were placed in
peritoneal cavity in another group of pregnant rats on
GD 12. The AT1-AA has been implicated in the patho-
genesis of preeclampsia both in humans and experimen-
tal models [12, 15, 16]. The antibody was used at a 1:40
dilution of the original purified stock as previously de-
scribed [13]. On GD 19, rats were prepared for measure-
ment of MAP and assessment of CBF autoregulation as
described above. In a separate group of animals, AT1-
AA or vehicle was infused as above. Rats were eutha-
nized on GD 19, and brains were collected to assess
water content using the wet:dry weight ratio as previ-
ously described [17].
Statistical analysis
Differences in CBF autoregulation curves for the Losar-
tan study were analyzed using a mixed effects model
three-way analysis of variance (ANOVA) with MAP as a
repeated measure and two (factors: group: sham versus
RUPP, and treatment: vehicle versus losartan). Similarly,
the curves for the AT1-AA study were analyzed using 2-
way repeated measures ANOVA with one factor (vehicle
versus AT1-AA antibody) and MAP as a matching vari-
able followed by Holm-Sidak post-hoc test. For the
losartan treatment, differences in pregnancy outcome
and mean arterial pressure were analyzed using 2-way
ANOVA with two factors (group: Sham versus RUPP,
and treatment: vehicle versus Losartan). For pregnancy
outcomes in the AT1-AA study, an unpaired t test was
used. A p value of less than 0.05 was considered sta-
tistically significant. All statistical analyses and figures
were calculated and generated using GraphPad Prism
(version 7.02).
Results
Impact of AT1 receptor blockade on pregnancy outcomes
A summary of pregnancy outcomes for rats treated with
losartan is provided in Table 1. Placental ischemia re-
sulted in a decrease in dam body mass which was not
prevented in losartan treated animals (p value for inter-
action = 0.863). Losartan did not prevent the reduction
in live pups typically induced by placental ischemia (p
value for interaction = 0.769) nor did it reduce the num-
ber of fetal resorptions in dams that remained pregnant
for the duration of the study (p value for interaction =
0.828). However, fewer losartan treated placental ische-
mic rats had complete (100%) resorption of all pups
(n = 4) compared with vehicle-treated placental ischemic
rats (n = 12). There was no effect of RUPP or losartan
treatment on pup (p value for interaction = 0.106) or
placental weight (p value for interaction = 0.058). Thus,
the general pregnancy outcomes were not altered in ani-
mals treated with losartan.
Losartan treatment prevents placental ischemia-induced
hypertension
Compared with sham pregnant rats, placental ischemia
caused a significant increase in mean arterial pressure
(116 ± 2 in RUPP vs. 101 ± 1mmHg in Sham; p < 0.05,
Fig. 1). Losartan treatment did not alter blood pressure in
the Sham group (97 ± 3mmHg), but it prevented RUPP-
induced increases in MAP (105 ± 3mmHg, p < 0.05).
There was no significant interaction between RUPP sur-
gery and losartan treatment (p = 0.239).
Table 1 Pregnancy outcomes in response to placental ischemia and losartan treatment
Characteristics Sham (N = 11) RUPP (N = 17) Sham + Los (N = 10) RUPP + Los (N = 17)
Body mass (g) 334.4 ± 6.5 298.2 ± 6.7* 337.0 ± 4.8† 300.7 ± 5.5*‡
No. of live pups 13 ± 0 7 ± 1* 13 ± 1† 7 ± 1*‡
No. of resorptions 0 ± 0 7 ± 1* 1 ± 0† 7 ± 1*‡
Pup weight (g) 2.29 ± 0.05 2.25 ± 0.04 2.49 ± 0.07 2.27 ± 0.06
Placenta weight (g) 0.46 ± 0.02 0.50 ± 0.02 0.51 ± 0.02 0.47 ± 0.02
*p < 0.05 vs. Sham
†p < 0.05 vs. RUPP
‡p < 0.05 vs. Sham + Los
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Losartan treatment prevents placental ischemia-induced
CBF autoregulation impairment
Changes in CBF in response to increased MAP were
compared in Sham rats, Sham rats treated with losartan,
RUPP, and RUPP rats treated with losartan. There was a
significant interaction between treatments and groups
(p = 0.013), the effect of MAP × group × treatment was
significantly different (0.0267), and there is a main effect
of losartan treatment on CBF (p < 0.014). At 180 mmHg
and above, the relative increase in CBF was significantly
greater in RUPP vehicle-treated vs. Sham rats receiving
vehicle. However, losartan treatment prevented this
RUPP-induced increase in CBF (p < 0.01 vs. RUPP;
Fig. 2a). Autoregulatory Index was calculated for each
MAP step and plotted in Fig. 2b. There was a significant
effect of treatment on autoregulatory index (p = 0.045)
calculated as the percent change in CBF divided by the
change in MAP. An index > 1, as shown in the RUPP an-
imals, is indicative of markedly impaired autoregulatory
function with a compliant vasculature. Autoregulatory
index was < 1 in all sham controls and in RUPP animals
treated with losartan. There was a significant effect of
group × treatment on CBF (p = 0.018). Expired carbon
dioxide was recorded throughout the study because
small increases in CO2 significantly increase CBF. There
was a main effect of group and treatment on CO2
(p < 0.0001); however, multiple comparisons analysis did
not yield any statistical differences across the groups.
While group × treatment effect was significantly differ-
ent (p < 0.0001), there was no significant effect of MAP
× group × treatment (p = 0.446) (Fig. 2c). Brain water
content, a marker of cerebral edema, was not different
between sham and RUPP rats treated with either vehicle
or losartan (Table 3).
AT1-AA infusion into pregnant rats impairs CBF
autoregulation
An agonistic AT1 receptor autoantibody has been re-
ported in women with preeclampsia [12]. The AT1-AA
has been proposed to enhance the sensitivity of AT1 re-
ceptors to the vasoconstrictor actions of AngII [13].
Therefore, we examined whether infusion of the AT1-
AA into normal pregnant rats would impair CBF auto-
regulation similar to what occurs in placental ischemic
rats. Table 2 shows the pregnancy outcomes for preg-
nant rats that received either a vehicle minipump or an
AT1-AA minipump. Chronic infusion of the AT1-AA
did not alter body weight, pup numbers, pup weight, or
placental weight. Mean arterial pressure was 105 ± 3
mmHg (n = 11) in the AT1-AA infused pregnant rats
compared with 98 ± 3mmHg (n = 7) in the vehicle in-
fused pregnant rats and was not different between the
groups. The infusion of the AT1-AA into pregnant rats
did not alter brain water content (Table 3). In a separate
group of animals, AT1-AA and vehicle infused pregnant
rats were anesthetized and intubated on GD 19 for as-
sessment of CBF autoregulation (Fig. 3). The infusion of
the AT1-AA significantly impaired the CBF response to
increasing arterial pressure. Consistent with impaired
autoregulatory function, autoregulatory index stayed < 1
in the normal pregnant rats, but was > 1 in AT1-AA in-
fused rats at the highest pressures.
Fig. 1 Losartan prevents placental ischemia-induced increase in blood pressure. Blood pressure was measured in conscious rats on GD19 via
indwelling carotid artery catheter. Data points for each rat are shown along with the Mean ± SEM. *p < 0.05 compared with Sham, #p < 0.05
compared with RUPP using 2-way ANOVA, with Holm-Sidak post hoc test. N = 9–17 rats per group/treatment. RUPP–reduced uterine
perfusion pressure
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Discussion
Cerebral complications are now considered a diagnostic
symptom of preeclampsia when accompanied by new
onset hypertension [18]. In addition, clinical studies in
preeclamptic patients point to vascular complications as
a major contributor to cerebral symptoms. Indeed, ap-
proximately 40% of (pre)eclampsia-related deaths can be
attributed to cerebrovascular events [2]. Therefore, con-
tinued investigation of the potential underlying mecha-
nisms that contribute to the cerebral consequences of
preeclampsia is required. The present study builds upon
the current literature by making the following important
advances. (1) The AT1 receptor contributes to the
pathogenesis of hypertension and to the impaired CBF
autoregulatory function in placental ischemic rats. (2)
An agonistic autoantibody to the AT1 receptor (AT1-
AA), which has been implicated in the pathogenesis of
preeclampsia by increasing AT1 receptor sensitivity, im-
pairs CBF autoregulation during pregnancy. Taken to-
gether, these data suggest that activation of the AT1
receptor may have important functional consequences in
the cerebral vasculature during pregnancy, perhaps in
part through a mechanism involving an agonistic AT1-
AA.
During a normal pregnancy, components of the RAS
are increased including renin, angiotensinogen, and al-
dosterone [6]. The increase in RAS during normal preg-
nancy is an important physiological adaptation that
promotes the normal extracellular fluid volume expan-
sion. Despite an increased circulating RAS, vascular sen-
sitivity to AngII is decreased such that greater than 2×
the normal amount is required to induce the same level
of vasoconstriction [19]. During a preeclamptic
Fig. 2 AT1R blockade prevents placental ischemia-induced impairments in CBF autoregulation. a Blood pressure was plotted against % change in
CBF for Sham (n = 4), RUPP (n = 7), Sham + losartan (n = 4), and RUPP+losartan (n = 3) groups. *p < 0.05 compared with Sham. #p < 0.05 compared
to Sham, Sham+losartan, RUPP+losartan. b Autoregulatory Index was plotted against changes in MAP. Dashed horizontal line (AI = 1) corresponds
to the complete loss of autoregulation. *p < 0.05 RUPP vs. Sham group effect. Data represent mean ± SEM. Statistics calculated using three way
repeated measures ANOVA
Table 2 Pregnancy outcomes in response to AT1-AA infusion
Characteristics Vehicle (N = 7) AT1-AA (N = 11)
Body mass (g) 312.7 ± 9.4 308.7 ± 6.8
No. of live pups 12 ± 0 11 ± 1
No. of resorptions 0 ± 0 0 ± 0
Pup weight (g) 2.43 ± 0.08 2.40 ± 0.07
Placenta weight (g) 0.59 ± 0.03 0.59 ± 0.04
Table 3 Brain water content [(wet-dry weight/wet weight)*100]
Experimental group Anterior brain (%) Posterior brain (%) n
Sham 79.4 ± 0.1 78.3 ± 0.2 7
RUPP 79.3 ± 0.1 78.0 ± 0.1 12
Sham+Los 79.1 ± 0.2 78.0 ± 0.2 5
RUPP+Los 78.5 ± 0.6 78.2 ± 0.2 8
Vehicle 79.9 ± 0.1 78.2 ± 0.1 7
AT1-AA 79.4 ± 0.6 78.0 ± 0.4 12
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pregnancy, considerable evidence in both humans and
experimental models suggest that vascular sensitivity to
AngII is increased. For example, a study from 1973 by
Gant et al. showed that vascular responses to AngII were
enhanced in primigravid women prior to the develop-
ment of pregnancy induced hypertension [20]. There is
also evidence for increased adrenal sensitivity to AngII
during pregnancies complicated by preeclampsia [20].
These data suggest a role for the AT1 receptor in the
pathogenesis of preeclampsia. Experimentally, the poten-
tial importance of the AT1 receptor was demonstrated
by incubating human umbilical vein endothelial cells
with serum from the RUPP model of placental ischemia.
In that study, serum from rats with placental ischemia
increased human umbilical vein endothelial cell produc-
tion of endothelin, an effect blocked by an AT1 receptor
inhibitor [21]. Moreover, a separate study reported that
AT1 receptor blockade in the RUPP model of placental
ischemia attenuates the hypertension [15]. The data in
the present study are consistent with an important role
for the RAS in the pathogenesis of preeclampsia, and
replicates earlier findings showing that blood pressure in
placental ischemic rats is sensitive to AT1 receptor
blockade.
Chronic AngII-induced hypertension directly causes
hypertrophic inward remodeling of the cerebral vascula-
ture which can negatively impact brain perfusion and
shift the range of autoregulation of CBF to higher pres-
sures (reviewed in [22–25]). However, there is an im-
portant sexually dimorphic response to chronic AngII
with blunted cerebral blood flow responses to AngII in
female mice compared with males suggesting that the
cerebral vasculature is regulated by AngII differently in
males and females [11]. While the role of AT1 receptors
in cerebral vascular function is generally well known, as
is their contribution to preeclampsia, much less is
understood about the contributions of the AT1 recep-
tors on the impaired CBF autoregulation during
preeclampsia. During a normal pregnancy, AT1 receptor
expression is reduced in the cerebral vasculature [26].
This reduction in receptor expression may contribute to
the protection against cerebral vascular inward
remodeling during hypertensive pregnancies. For ex-
ample, both nitro-L-arginine–induced hypertensive and
Dahl S hypertensive rats are protected against cerebral
vascular remodeling during pregnancy [27, 28]. Consist-
ent with these findings, we previously reported that cere-
bral vessels from placental ischemic rats do not undergo
inward remodeling [17]. In addition, we showed that
CBF autoregulation is impaired in the placental ischemic
model caused by RUPP [5]. The present study confirms
and extends upon these findings by showing that the
impaired autoregulatory function can be ameliorated
with AT1 receptor blockade, thus suggesting a mechan-
istic role for the AT1 receptors.
The cellular pathway by which AT1 receptor blockade
during placental ischemia improves autoregulatory func-
tion remains unclear, although one can speculate as to
possibilities. For example, it has been previously shown
that treatment with losartan increases the amount of
AngIV produced which ultimately leads to an increased
AngIII production and activation of the vascular protect-
ive AT2 receptor [29]. Another possibility may relate to
evidence showing that AngII reduces immunolabeled
βENaC in renal vascular smooth muscle [30]. This is po-
tentially important because βENaC is an essential
Fig. 3 Chronic infusion of AT1-AA into pregnant rats induced impaired CBF autoregulation. a Changes in CBF were plotted against mean arterial
pressure in vehicle—(n = 3) or AT1-AA—(n = 4) infused rats. b Autoregulatory index was calculated for each pressure step and plotted against
changes in MAP. Dashed horizontal line (AI = 1) corresponds to the complete loss of autoregulation. Data represent mean ± SEM. *p < 0.05
compared with vehicle. #p < 0.05 AT1-AA at 190 mmHg vs AT1-AA at 100 mmHg. Statistics were calculated using two-way repeated
measures ANOVA
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component of the vascular mechanosensor that contrib-
utes to the myogenic response [31], and we previously
showed that βENaC protein expression is lower in cere-
bral arteries from placental ischemic rats when com-
pared with normal pregnant rats [17]. Therefore, if
cerebral vascular responses to AngII mirror those in the
renal vasculature, it may be that angiotensin mediated
downregulation of βENaC is a contributing mechanism.
Another possibility by which AngII can induce impaired
vascular reactivity is through generation of reactive oxy-
gen species (ROS) (reviewed extensively in [22]). Thus, it
is possible that increased vascular ROS production in
the setting of placental ischemia, primes the vasculature
for increased injury in response to endogenous and ex-
ogenous levels of AngII or AT1-AA. This possibility will
be addressed in future studies.
We also considered the possibility of a role for the
AT1-AA. AT1-AA was first reported in women with
preeclamptic pregnancies by Wallukat et al. [12]. AT1-
AA is thought to act by increasing the sensitivity of the
AT1 receptor; however, its role in the cerebral vascula-
ture has not been examined until now. Previously pub-
lished work from the LaMarca laboratory reports that
placental ischemia increases the production of AT1-AA
in rats [15]. Moreover, infusion of the AT1-AA into
pregnant rats replicates features of the placental ische-
mic model including the hypertension [32]. In the
present study, infusion of the AT1-AA did not increase
MAP. This result is more in line with the work of Wen-
zel et al. who generated an activating AT1 receptor anti-
body (AT1-AB) with the same chronotropic activity as
the AT1-AA, but by itself did not cause changes in MAP
in pregnant rats [33]. The reason for the difference in
blood pressure response is not clear; however, it may be
due to genetic differences in the rats used in the studies.
The original studies utilized Sprague Dawley (SD) rats,
whereas the present study was performed in CD rats, a
sub-strain of SD rats. Interestingly, infusion of the AT1-
AA caused impaired CBF autoregulation in pregnant
rats, suggesting that it may play a mechanistic role in
the cerebral vascular changes during preeclampsia inde-
pendent of changes in blood pressure.
Conclusions
Although cerebrovascular events contribute significantly
to the morbidity and mortality in patients with pre-
eclampsia, the mechanisms involved are not clear. In this
study, we present evidence that blockade of the AT1 re-
ceptor with losartan following placental ischemia pre-
vents the hypertension and loss of CBF autoregulation
associated with preeclampsia. It remains to be deter-
mined whether the lowering of blood pressure or block-
ade of the receptor is responsible for the improvement.
While our data support the idea that the AT1 receptor
is a promising therapeutic target for the treatment of
cerebrovascular abnormalities associated with placental
ischemia and preeclampsia, RAS inhibition is contraindi-
cated during pregnancy. In addition, we cannot rule out
the possibility that AngII or AT1-AA are not directly
impacting cerebral vascular function, but rather having
an indirect effect in the brain due to actions in other or-
gans. Therefore, tissue specific therapies that target the
AT1 receptor or the AT1-AA may be useful as potential
therapeutic agents.
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